Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Ding

Showing results (451-460 of 460) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 460 results.
Nature Communications|February 17, 2019
Highly efficient photothermal nanoagent achieved by harvesting energy via excited-state intramolecular motion within nanoparticlesZheng Zhao, Chao Chen, Wenting Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 15, 2024
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancerJiliang Zhao, Han Wang, Chunlei Wang, et al.
Cell Reports. Medicine|March 27, 2026
Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapyYanqin Liu, Jiliang Zhao, Kailu Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 5, 2026
Cortical Somatostatin Neurons Regulate Seizure Susceptibility via MINAR1/Gαs-cAMP SignalingWei-Tang Liu, Zhi-Bin Hu, Ling Hu, et al.
Faraday Discussions|February 8, 2017
Biomedical applications of luminogens: general discussionAndrea Pucci, Andy Hor, Meng Gao, et al.
Journal for Immunotherapy of Cancer|March 30, 2026
HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clusteringJiliang Zhao, Dongping Zhang, Yun-Yueh Lu, et al.
Lancet (London, England)|May 20, 2020
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialYeming Wang, Dingyu Zhang, Guanhua Du, et al.
Journal of Affective Disorders|February 20, 2021
Disrupted hemispheric connectivity specialization in patients with major depressive disorder: Evidence from the REST-meta-MDD ProjectYu-Dan Ding, Ru Yang, Chao-Gan Yan, et al.
Translational Psychiatry|June 6, 2022
Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorderYu-Dan Ding, Xiao Chen, Zuo-Bing Chen, et al.
ACS Nano|July 24, 2023
Aggregation-Induced Emission (AIE), Life and HealthHaoran Wang, Qiyao Li, Parvej Alam, et al.
Pageof 46

Showing results (451-460 of 460) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 460 results.
Nature Communications|February 17, 2019
Highly efficient photothermal nanoagent achieved by harvesting energy via excited-state intramolecular motion within nanoparticlesZheng Zhao, Chao Chen, Wenting Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 15, 2024
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancerJiliang Zhao, Han Wang, Chunlei Wang, et al.
Cell Reports. Medicine|March 27, 2026
Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapyYanqin Liu, Jiliang Zhao, Kailu Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 5, 2026
Cortical Somatostatin Neurons Regulate Seizure Susceptibility via MINAR1/Gαs-cAMP SignalingWei-Tang Liu, Zhi-Bin Hu, Ling Hu, et al.
Faraday Discussions|February 8, 2017
Biomedical applications of luminogens: general discussionAndrea Pucci, Andy Hor, Meng Gao, et al.
Journal for Immunotherapy of Cancer|March 30, 2026
HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clusteringJiliang Zhao, Dongping Zhang, Yun-Yueh Lu, et al.
Lancet (London, England)|May 20, 2020
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialYeming Wang, Dingyu Zhang, Guanhua Du, et al.
Journal of Affective Disorders|February 20, 2021
Disrupted hemispheric connectivity specialization in patients with major depressive disorder: Evidence from the REST-meta-MDD ProjectYu-Dan Ding, Ru Yang, Chao-Gan Yan, et al.
Translational Psychiatry|June 6, 2022
Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorderYu-Dan Ding, Xiao Chen, Zuo-Bing Chen, et al.
ACS Nano|July 24, 2023
Aggregation-Induced Emission (AIE), Life and HealthHaoran Wang, Qiyao Li, Parvej Alam, et al.
Pageof 46